PACS Group, Inc. (NYSE: PACS) is a Healthcare company in the Medical - Care Facilities industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
44.81
+0.31+0.70%
Filing
Up 0.7% — Filed an 8-K material-event report (2026-08-04) — details in the filing.
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | 29.68 | EPS (ttm) | 1.51 | Insider Own | - | Shs Outstand | 158.27M | Perf Week | -4.58% |
| Market Cap | 7.09B | Forward P/E | 18.02 | EPS next Y | 2.49 | Insider Trans | -0.76% | Shs Float | 47.78M | Perf Month | -0.42% |
| Enterprise Value | 10.17B | PEG | 3.21 | EPS next Q | - | Inst Own | - | Short Float | 2.86% | Perf Quarter | 37.79% |
| Income | 244.00M | P/S | 1.31 | EPS this Y | 51.52% | Inst Trans | - | Short Ratio | 4.91 | Perf Half Y | 26.58% |
| Sales | 5.43B | P/B | 6.81 | EPS next Y | 8.65% | ROA | 4.30% | Short Interest | 4.53M | Perf YTD | 16.72% |
| Book/sh | 6.58 | P/C | 28.60 | EPS next 5Y | 9.24% | ROE | 26.63% | 52W High | 48.00 -6.65% | Perf Year | 321.94% |
| Cash/sh | 1.57 | P/FCF | 30.72 | EPS past 3/5Y | 6.85% - | ROIC | 5.47% | 52W Low | 7.50 497.47% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | 22.90 | Sales past 3/5Y | 29.74% - | Gross Margin | 19.19% | Volatility | 4.19% 4.29% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 1.87 | EPS Y/Y TTM | 297.37% | Oper. Margin | 7.02% | ATR (14) | 1.99 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.99 | Sales Y/Y TTM | 32.81% | Profit Margin | 4.49% | RSI (14) | 53.20 | Recom | 2.13 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.99 | EPS Q/Q | 19.05% | SMA20 | -1.07% | Beta | 0.39 | Target Price | 52.25 |
| Payout | 0.00% | Debt/Eq | 3.59 | Sales Q/Q | 11.20% | SMA50 | 8.98% | Rel Volume | 1.35 | Prev Close | 44.50 |
| Employees | 47,455 | LT Debt/Eq | 3.58 | Earnings | Nov 25 | SMA200 | 31.53% | Avg Volume | 946.86K | Price | 44.81 |
| IPO Date | Apr 11, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 25.06% 4.13% | Net Debt/EBITDA | 7.33 | Volume | 1,274,123 | Change | 0.70% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-08-26 | Reiterated | UBS | Buy | $42 → $57 |
| May-18-26 | Reiterated | Truist Securities | Buy | $40 → $52 |
| May-13-26 | Reiterated | Oppenheimer | Outperform | $40 → $48 |
| Feb-27-26 | Reiterated | RBC Capital | Outperform | $47 → $52 |
| Dec-19-25 | Reiterated | RBC Capital | Outperform | $33 → $47 |
| Dec-18-25 | Resumed | UBS | Buy | $42 |
| Dec-12-25 | Reiterated | Truist Financial | Buy | $32 → $40 |
| Nov-20-25 | Reiterated | RBC Capital | Outperform | $30 → $33 |
| Dec-17-24 | Downgrade | JP Morgan | Overweight → Neutral | |
| Aug-15-24 | Reiterated | Truist Securities | Buy | $32 → $44 |
Latest News
Aug-04-26
Jul-30-26
Jul-28-26
Jul-28-2604:30PM
Jul-23-26
Jul-23-2607:00AM
Jul-17-26
Jul-14-26
12:40PM
10:05AM
Jul-08-26
Jun-30-26
Jun-29-26
Jun-29-2604:05PM
Company
PACS Group, Inc. operates as a holding company, primarily focused on delivering post-acute healthcare services. This encompasses operating various facilities, providing skilled professionals, and offering essential ancillary support. The company further specializes in providing a spectrum of senior living options, encompassing dedicated senior care, assisted living, and independent living residences in select communities. Founded in 2013 by Jason Murray and Mark Hancock, its corporate headquarters are located in Farmington, Utah.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | 5,432 | 5,289 | 4,090 | 3,111 | 2,422 | 1,167 | |
| Cost of Goods Sold Incl. D&A | 4,389 | 4,130 | 3,297 | 2,664 | 2,021 | 979 | |
| Gross Profit | 1,042 | 1,159 | 793 | 447 | 401 | 187 | |
| Selling, General and Administrative Excl. Other | 428 | 415 | 344 | 214 | 149 | 97 | |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other Operating Expense | 233 | 435 | 326 | 25 | 22 | 7 | |
| Operating Income | 381 | 310 | 123 | 208 | 229 | 83 | |
| Interest Expense | 28 | 28 | 44 | 50 | 26 | 5 | |
| Unusual Expense | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 2 | 3 | 23 | -1 | 3 | 3 | |
| Net Income Before Taxes | 356 | 284 | 102 | 157 | 207 | 81 | |
| Income Taxes | 112 | 93 | 46 | 44 | 57 | 33 | |
| Consolidated Net Income | 244 | 192 | 56 | 113 | 150 | 48 | |
| Net Income From Continuing Operations | 244 | 192 | 55 | 113 | 150 | 48 | |
| Net Income | 244 | 192 | 56 | 113 | 150 | 48 | |
| EPS (Recurring) | 1.55 | 1.23 | 0.38 | 0.75 | 1.00 | 0.32 | |
| EPS (Basic, Before Extraordinaries) | 1.55 | 1.23 | 0.38 | 0.75 | 1.00 | 0.32 | |
| EPS (Diluted) | 1.51 | 1.22 | 0.38 | 0.75 | 1.00 | 0.32 | |
| EBITDA | 444 | 366 | 187 | 233 | 255 | 94 | |
| Other After Tax Adjustments | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | |
| Price To Earnings Ratio | 29.68 | 31.47 | 34.50 | — | — | — | |
| Price To Sales Ratio | 1.30 | 1.13 | 0.47 | — | — | — | |
| Gross Margin | 19.18 | 21.91 | 19.39 | 14.37 | 16.56 | 16.02 | |
| Operating Margin | 7.01 | 5.86 | 3.01 | 6.69 | 9.45 | 7.11 | |
| Net Margin | 4.49 | 3.63 | 1.37 | 3.63 | 6.19 | 4.11 | |
| Shares Outstanding | 157 | 156 | 147 | 150 | 150 | 150 | |
| Market Capitalization | 7,035 | 5,989 | 1,927 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hancock Mark | director, 10 percent owner: | Jul 15 '26 | Sale | 45.05 | 3,332 | 150,115 | 53,906,884 | Jul 16 |
| Jergensen Joshua | President & COO | Jul 15 '26 | Sale | 45.02 | 40,000 | 1,800,718 | 2,576,320 | Jul 16 |
| Hancock Mark | director, 10 percent owner: | Jul 14 '26 | Sale | 45.03 | 10,296 | 463,680 | 53,910,216 | Jul 16 |
| Hancock Mark | director, 10 percent owner: | Jul 09 '26 | Sale | 45.06 | 4,966 | 223,781 | 53,920,512 | Jul 10 |
| Hancock Mark | director, 10 percent owner: | Jul 08 '26 | Sale | 45.07 | 20,338 | 916,611 | 53,925,478 | Jul 10 |
| Lewis Michelle Renee | Chief Accounting Officer | Jul 06 '26 | Sale | 45.04 | 4,137 | 186,333 | 355,338 | Jul 06 |
| Hancock Mark | director, 10 percent owner: | Jul 06 '26 | Sale | 45.33 | 142,163 | 6,444,860 | 53,945,816 | Jul 06 |
| Hancock Mark | director, 10 percent owner: | Jul 02 '26 | Sale | 45.01 | 12,825 | 577,290 | 54,087,979 | Jul 06 |
| Lewis Michelle Renee | Chief Accounting Officer | Jul 02 '26 | Sale | 45.03 | 6,663 | 300,032 | 359,475 | Jul 06 |
| Hancock Mark | director, 10 percent owner: | Jul 01 '26 | Sale | 45.02 | 6,080 | 273,716 | 54,100,804 | Jul 06 |
| Lewis Michelle Renee | Chief Accounting Officer | Jul 01 '26 | Sale | 45.01 | 4,200 | 189,059 | 366,138 | Jul 06 |
| Hancock Mark | Co Fndr; Exec V Chair | Jun 26 '26 | Sale | 40.50 | 61,931 | 2,508,085 | 54,102,597 | Jun 26 |
| Lewis Michelle Renee | Chief Accounting Officer | Jun 25 '26 | Sale | 40.01 | 15,000 | 600,179 | 370,338 | Jun 26 |
| Hancock Mark | Co Fndr; Exec V Chair | Jun 25 '26 | Sale | 40.33 | 138,069 | 5,567,701 | 54,164,528 | Jun 26 |
| Hancock Mark | Co Fndr; Exec V Chair | Jun 17 '26 | Sale | 35.31 | 63,680 | 2,248,415 | 54,302,597 | Jun 22 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.